Lensgen

New Innovator

LensGen® is a clinical stage company based in Irvine, California focused on restoring youthful vision to millions of cataract and presbyopia patients with a dynamic, continuous focus fluid-optic intraocular lens called Juvene™.

Juvene is designed to permanently restore clear and continuous vision at all distances with high quality optics throughout the range. Juvene fills the entire volume of the capsule for optimal lens stability and PCO prevention. The lens is implanted using current surgical techniques used for traditional intraocular lenses.

LensGen has raised $3.6 million in early equity rounds and $28.2 million in Series A financing. The company plans to open a $60 million Series B round in the middle of 2019. Series B proceeds will be used to complete an FDA study and PMA approval for Juvene and Juvene Toric.

For more information, please visit www.lensgen.com